Eli Lilly and Company $LLY Shares Newly Bought by Polaris Financial Partners

Polaris Financial Partners bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, HoldingsChannel reports. The firm bought 464 shares of the company’s stock, valued at approximately $551,000.

Several other large investors have also modified their holdings of the business. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.5%

NYSE LLY traded down $5.65 during trading on Friday, hitting $1,144.20. The company’s stock had a trading volume of 2,051,176 shares, compared to its average volume of 2,987,583. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market cap of $1.08 trillion, a PE ratio of 38.40, a P/E/G ratio of 1.42 and a beta of 0.46. The business’s 50 day simple moving average is $1,177.37 and its 200-day simple moving average is $1,088.38. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday. HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Citigroup raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. Finally, Leerink Partners increased their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,311.96.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded Jaypirca (pirtobrutinib) for certain adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. The first-line approval broadens the drug’s addressable market and could support future oncology revenue. Jaypirca FDA expanded indication
• Positive Sentiment: New data strengthened Lilly’s obesity and diabetes pipeline. The oral GLP-1 Foundayo (orforglipron) demonstrated cardiovascular safety, sustained A1C and weight benefits, and favorable predicted reductions in long-term diabetes and cardiovascular risk. Foundayo risk-reduction data
• Positive Sentiment: Mid-stage results for EloraTZP, a combination of eloralintide and tirzepatide, showed weight loss of as much as 23.3% after 48 weeks in patients with type 2 diabetes. The results support Lilly’s strategy of adding amylin-based therapies to Zepbound and Mounjaro, potentially extending its obesity-market lead. EloraTZP obesity data
• Neutral Sentiment: Lilly received permits for a planned $3 billion pharmaceutical plant in Katwijk, Netherlands. The facility may expand long-term manufacturing capacity, but construction spending and the extended timeline limit any immediate earnings effect. Katwijk plant permits
• Negative Sentiment: Lilly ended its cancer-development partnership with Foghorn Therapeutics after disappointing early results. The move appears financially limited for Lilly but highlights pipeline execution risk and resulted in major layoffs at Foghorn. Foghorn partnership termination
• Negative Sentiment: Investors remain concerned that lower Zepbound and Mounjaro pricing could pressure revenue growth. LLY also trades at a demanding valuation, while a late-session decline in healthcare stocks added broader market pressure.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.